Dr. Julia S. Arzeno, MD

Dr. Arzeno practices at Orchard Creek Surgery Center - Mountain View in Mountain View, California.

Dr. Arzeno's NPI, 1578094785, was assigned on March 21, 2017. Dr. Arzeno graduated from David Geffen School of Medicine at UCLA in 2017. Dr. Arzeno holds California license A160666.

Dr. Arzeno's primary practice is Orchard Creek Surgery Center - Mountain View, at 525 South Drive, Suite 115, Mountain View, CA 94040. The practice phone is (650) 969-5600.

Dr. Arzeno's primary practice is Orchard Creek Surgery Center - Mountain View in Mountain View, California. Dr. Arzeno is also affiliated with Stanford Health Care Tri-Valley. The medical group on file is Schweiger Dermatology Group, San Pedro. Dmand AI also links Dr. Arzeno to 1 more ambulatory surgery center and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Arzeno practices, 3 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Arzeno's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Arzeno is board certified in dermatology by the American Board of Dermatology. Dr. Arzeno is licensed in California.

Dmand AI lists acute skin infection, benign or precancerous skin growths, cancerous skin growth removal, minor head injury, minor injury to a limb, rash, skin cyst and skin discoloration among the conditions Dr. Arzeno treats.

CMS data shows 2,079 Medicare services from Dr. Arzeno across 30 procedure codes in 2024, for 597 Medicare patients. Medicare paid $603,834 for them. Every service was in an office.

CMS counts 597 Medicare patients who saw Dr. Arzeno in 2024. The largest group is 75 to 84, with 241 patients. 75% of them have high cholesterol, and 71% have high blood pressure. 7% are also on Medicaid. Their average risk score is 1.19, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Arzeno's median patient age at 63, with 56% women.

In 2024, Dr. Arzeno wrote 910 Medicare Part D claims for 500 patients. 100% of them were for generic drugs. CMS names the drug for 856 of them, across 7 drugs with 11 or more claims each, at $7,234 in total drug cost. In 2023, CMS named 1,190 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 99 out of 100 for Dr. Arzeno for performance year 2024, reported as part of a group. Dr. Arzeno accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 182 procedures of melanoma (skin cancer) excision by Dr. Arzeno, more than 97% of the clinicians it reports for that procedure.

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 11 papers to Dr. Arzeno, published from 2011 to 2022. 2020 was the busiest year, with 4. The most frequent topics are Skin Neoplasms, Carcinoma, Squamous Cell and Mohs Surgery. Dr. Arzeno has published most often in J Am Acad Dermatol. Dr. Arzeno's most frequent co-authors are Naomi Amanda So, MD, Daniel Q. Bach, MD and Laura Yu Blumenthal, MD.

CMS Open Payments shows 79 general payments to Dr. Arzeno from 16 drug and device companies from 2021 to 2025. Food and beverage make up the largest share, 100% of the total. Abbvie Inc. paid the most, $403.

Dr. Arzeno graduated from David Geffen School of Medicine at UCLA in 2017.

Dr. Arzeno is in network with 15 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.